Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis deutschland gmbh - insulin glargine - solution for injection - 300iu/ml

Israel - English - Ministry of Health

sanofi israel ltd - caplacizumab - powder and solvent for solution for injection - caplacizumab 10 mg/vial - caplacizumab - cablivi is indicated for the treatment of adults and adolescents of 12 years of age and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (attp), in conjunction with plasma exchange and immunosuppression.

Egypt - English - EDA (Egyptian Drug Authority)

sanofi aventis-egypt - injection - 20 mg

Egypt - English - EDA (Egyptian Drug Authority)

sanofi aventis-egypt - injection - 20 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

European Union - English - EMA (European Medicines Agency)

aventis pharma s.a. - telithromycin - community-acquired infections; pharyngitis; bronchitis, chronic; pneumonia; tonsillitis; sinusitis - antibacterials for systemic use, - when prescribing levviax consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1).levviax is indicated for the treatment of the following infections:in patients of 18 years and older:-community-acquired pneumonia, mild or moderate (see section 4.4).- when treating infections caused by known or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1):- acute exacerbation of chronic bronchitis,- acute sinusitisin patients of 12 years and older:- tonsillitis/pharyngitis caused by streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriate in countries/regions with a significant prevalence of macrolide resistant s. pyogenes, when mediated by ermtr or mefa (see sections 4.4 and 5.1).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -